Effects of 2-Aticyto Complex and D-Ribose on Pain and Clinical Course in Patients With Fibromyalgia
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07495943, who can take part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Haydarpasa Numune Training and Research Hospital
- Trial code
- NCT07495943
- Record updated
- 21 September 2026
- Original description
This multicenter, randomized, double-blind, placebo-controlled study will evaluate whether an oral supplement containing 2-Aticyto Complex and D-ribose (FibroThol), added to ongoing standard medical treatment, improves pain, symptoms, and clinical course in adults with fibromyalgia syndrome. Eligible participants are adults aged 18 to 65 years who have had fibromyalgia for at least 1 year and have been receiving pregabalin and/or duloxetine for at least 3 months. Participants will be randomly assigned to receive either FibroThol or placebo, administered as 15 mL three times daily for 4 weeks, while continuing their existing treatment. Follow-up assessments will be performed at baseline, week 2, and week 4 using patient-reported symptom and function measures. The study aims to determine whether this supportive supplement provides additional benefit compared with placebo in patients with persistent symptoms despite standard therapy.Read full original descriptionShow less
Effects of 2-Aticyto Complex and D-Ribose on Pain, Symptoms, and Clinical Course in Patients With Fibromyalgia Syndrome
This multicenter, randomized, double-blind, placebo-controlled study will evaluate whether an oral supplement containing 2-Aticyto Complex and D-ribose (FibroThol), added to ongoing standard medical treatment, improves pain, symptoms, and clinical course in adults with fibromyalgia syndrome. Eligible participants are adults aged 18 to 65 years who have had fibromyalgia for at least 1 year and have been receiving pregabalin and/or duloxetine for at least 3 months. Participants will be randomly assigned to receive either FibroThol or placebo, administered as 15 mL three times daily for 4 weeks, while continuing their existing treatment. Follow-up assessments will be performed at baseline, week 2, and week 4 using patient-reported symptom and function measures. The study aims to determine whether this supportive supplement provides additional benefit compared with placebo in patients with persistent symptoms despite standard therapy.
Inclusion: Adults aged 18 to 65 years; Diagnosis of fibromyalgia syndrome according to the 2016 ACR criteria; Followed in a physical medicine and rehabilitation outpatient clinic for at least 1 year; Receiving pregabalin and/or duloxetine treatment for at least 3 months; Able to live independently in the community; Literate and able to record symptoms and responses; No cognitive dysfunction that would interfere with answering study questions; Able and willing to provide informed consent.
Exclusion: Rheumatologic disease; Renal failure; Hepatic failure; Cardiovascular disease; Hypoglycemia or diabetes mellitus; Any neurologic disease (such as stroke, spinal cord injury, multiple sclerosis, or Parkinson's disease); Known allergy or hypersensitivity to any active or excipient component of the study syrup; Active malignancy; Active infection; Severe psychiatric disease that may interfere with study participation or assessment; Use of any other dietary supplement or nutritional support product during the study period; Pregnancy or lactation; Refusal to participate or inability to provide informed consent.